The first needle-free COVID-19 vaccine is here and China became the first country to approve it. The vaccine, created by Tianjin-based CanSino Biologics, needs to be inhaled and it is expected to&nbsp;quickly become a favourite among a number of people who are not comfortable with needles and syringes.&nbsp;

According to a statement to the Hong Kong Stock Exchange, the vaccine called CanSino’s Ad5-nCoV has received approval from the China’s National Medical Products Administration. The news produced an instant movement in the market as the share prices of the company went up by around 14.5 per cent.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/canada-at-least-10-killed-in-mass-stabbings-all-you-need-to-know-about-the-incident-513012">Canada: 10 killed in mass stabbings. All you need to know about the incident</a>

The company came up with their one-shot Covid drug which were used in China, Pakistan, Hungary, Mexico and Malaysia after completing human testing in March 2020. This new drug is the updated version developed by the company to boost protection against the COVID-19 virus.&nbsp;

According to Bloomberg, the vaccine can be self-administered and that makes it quite lucrative for the healthcare sector as it will significantly reduce the personnel needed for the activity. It also starts working quickly as it directly stimulates antibodies in “nasal and airway tissues” to defend against Covid.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/volodymyr-zelensky-claims-ukraine-takes-three-settlements-in-south-and-east-in-counter-offensive-512978">Ukraine takes three settlements in south and east in counter-offensive</a>

Right now, the one-shot vaccine was found to be 66 per cent effective when it comes to Covid prevention and around 91 per cent effective when it comes to other severe diseases. &nbsp;

This is not the first Covid vaccine that can be inhaled as similar products were also developed by AstraZeneca&nbsp;and&nbsp;Johnson &amp; Johnson but this was the first one to get approved.&nbsp;

(With inputs from agencies)

WATCH WION LIVE HERE -

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

The first needle-free COVID-19 vaccine is here and China became the first country to approve it. The vaccine, created by Tianjin-based CanSino Biologics, needs to be inhaled and it is expected to quickly become a favourite among a number of people who are not comfortable with needles and syringes.

The first needle-free COVID-19 vaccine is here and China became the first country to approve it. The vaccine, created by Tianjin-based CanSino Biologics, needs to be inhaled and it is expected to quickly become a favourite among a number of people who are not comfortable with needles and syringes. According to a statement to the Hong Kong Stock Exchange, the vaccine called CanSino’s Ad5-nCoV has received approval from the China’s National Medical Products Administration. The news produced an instant movement in the market as the share prices of the company went up by around 14.5 per cent. Also read | Canada: 10 killed in mass stabbings. All you need to know about the incident The company came up with their one-shot Covid drug which were used in China, Pakistan, Hungary, Mexico and Malaysia after completing human testing in March 2020. This new drug is the updated version developed by the company to boost protection against the COVID-19 virus. According to Bloomberg, the vaccine can be self-administered and that makes it quite lucrative for the healthcare sector as it will significantly reduce the personnel needed for the activity. It also starts working quickly as it directly stimulates antibodies in “nasal and airway tissues” to defend against Covid. Also read | Ukraine takes three settlements in south and east in counter-offensive Right now, the one-shot vaccine was found to be 66 per cent effective when it comes to Covid prevention and around 91 per cent effective when it comes to other severe diseases. This is not the first Covid vaccine that can be inhaled as similar products were also developed by AstraZeneca and Johnson & Johnson but this was the first one to get approved. (With inputs from agencies) WATCH WION LIVE HERE -

China approves world's first inhaled COVID-19 vaccine for emergency use

A team from the University of Iowa and the University of Georgia discovered that the intranasal COVID-19 vaccine protects mice against deadly coronavirus infection.

The vaccine also prevents the Coronavirus from spreading from animal to animal.

The findings were reported in the scientific journal 'Science Advances' on July 2.&nbsp;

"If this new COVID-19 vaccine proves successful in people, it could help manage the COVID-19 pandemic by preventing SARS-CoV-2 transmission," says Paul McCray, co-leader of the study.&nbsp;

Inhalation rather than injection&nbsp;

Unlike traditional vaccinations, which require an injection, this vaccine is delivered via nasal spray, similar to those used to prevent influenza.

The vaccination used in the trial only requires a single dose and can be kept in the refrigerator for up to three months at normal conditions.&nbsp;

The experimental vaccination delivers the SARS-CoV-2 spike protein into cells via a harmless parainfluenza virus 5 (PIV5), which triggers an immune response that protects against COVID-19 infection.

PIV5 is linked to common cold viruses and infects a variety of species, including humans, without causing sickness.&nbsp;

If successful, the nasal vaccine will be a game-changer, especially for kids who need to be vaccinated against COVID-19.&nbsp;

(With inputs from agencies)

A team from the University of Iowa and the University of Georgia discovered that the intranasal COVID-19 vaccine protects mice against deadly coronavirus infection.

A team from the University of Iowa and the University of Georgia discovered that the intranasal COVID-19 vaccine protects mice against deadly coronavirus infection. The vaccine also prevents the Coronavirus from spreading from animal to animal. The findings were reported in the scientific journal 'Science Advances' on July 2. "If this new COVID-19 vaccine proves successful in people, it could help manage the COVID-19 pandemic by preventing SARS-CoV-2 transmission," says Paul McCray, co-leader of the study. Inhalation rather than injection Unlike traditional vaccinations, which require an injection, this vaccine is delivered via nasal spray, similar to those used to prevent influenza. The vaccination used in the trial only requires a single dose and can be kept in the refrigerator for up to three months at normal conditions. The experimental vaccination delivers the SARS-CoV-2 spike protein into cells via a harmless parainfluenza virus 5 (PIV5), which triggers an immune response that protects against COVID-19 infection. PIV5 is linked to common cold viruses and infects a variety of species, including humans, without causing sickness. If successful, the nasal vaccine will be a game-changer, especially for kids who need to be vaccinated against COVID-19. (With inputs from agencies)

Nasal COVID-19 vaccine protects animals from the deadly infection

inhaled-covid-19-vaccine

Inhaled Covid 19 Vaccine, News on Inhaled Covid 19 Vaccine, stories on Inhaled Covid 19 Vaccine, articles on Inhaled Covid 19 Vaccine, Inhaled Covid 19 Vaccine stories at Wion, Inhaled Covid 19 Vaccine news, Inhaled Covid 19 Vaccine latest news

inhaled covid-19-vaccine

China approves world's first inhaled COVID-19 vaccine for emergency use

Nasal COVID-19 vaccine protects animals from the deadly infection